1. Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial. (April 2021) Authors: Martin, M.; Holmes, F.A.; Moy, B.; Mansi, J.; Gnant, M.; Buyse, M.; Barrios, C.; Bryce, R.; Wong, A.; Chan, A. Journal: Breast Issue: Volume 56(2021)Supplement 1 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy of neratinib in hormone receptor-positive (HR+) patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+ early-stage breast cancer (BC): subgroup analyses from the phase III ExteNET trial. (March 2019) Authors: Ejlertsen, B.; Holmes, F.A.; Chia, S.K.L.; Iwata, H.; Moy, B.; Delaloge, S.; Xu, F.; Barnett, B.; Chan, A.; Martin, M. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Population effectiveness model of the consequences of recurrences following treatment with trastuzumab among women with HER2+ early stage breast cancer in the United States. (March 2019) Authors: Doan, Q.; Martin, M.; Lalla, D.; Halperin, M.; Barnett, B.; Bryce, R.; Danese, M.; Moy, B. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011. (February 2017) Authors: Chavarri-Guerra, Y.; St. Louis, J.; Bukowski, A.; Soto-Perez-de-Celis, E.; Liedke, P.E.R.; Symecko, H.; Moy, B.; Higgins, M.; Finkelstein, D.M.; Goss, P.E. Journal: Breast Issue: Volume 31(2017) Page Start: 197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗